In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Meticillin-resistant Staphylococcus aureus (MRSA) presents a significant global health threat.
• Increasing resistance to existing antibiotics, including linezolid, necessitates the exploration of novel therapeutic strategies.
• Ceftaroline is a key antibiotic for MRSA infections, but resistance can emerge.

Purpose of the Study:

• To evaluate the in vitro efficacy of ceftaroline in combination with other antibiotics against MRSA.
• To compare the effectiveness of different antibiotic combinations against MRSA isolates, including those with dual resistance to methicillin and linezolid.
• To identify synergistic or additive effects of ceftaroline-based combinations.

Main Methods:

• In vitro susceptibility testing was performed on 61 MRSA isolates using the overlapping E-test method.
• Fractional inhibitory concentration (FIC) index was calculated to assess drug interactions.
• Combinations tested included ceftaroline with daptomycin, vancomycin, and linezolid.

Main Results:

• Daptomycin-ceftaroline combinations demonstrated significantly lower FIC values compared to vancomycin-ceftaroline or linezolid-ceftaroline against MRSA (P<0.05).
• All MRSA strains, including those resistant to linezolid, were resistant to ceftaroline monotherapy.
• Ceftaroline combined with vancomycin or daptomycin exhibited higher rates of synergy or addition than combinations involving linezolid.

Conclusions:

• Daptomycin-ceftaroline represents a potentially effective combination therapy against challenging MRSA isolates, including linezolid-resistant strains.
• Vancomycin or daptomycin in combination with ceftaroline may offer superior synergistic activity compared to linezolid-based combinations.
• Further clinical investigation is warranted to confirm the efficacy of these combinations in treating MRSA infections.